You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEthchlorvynol
Accession NumberDB00189  (APRD00958)
TypeSmall Molecule
GroupsApproved, Illicit, Withdrawn
DescriptionEthchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists. [Wikipedia]
Structure
Thumb
Synonyms
1-chloro-3-ethyl-1-penten-4-yn-3-ol
1-Chloro-3-ethyl-pent-1-en-4-yn-3-ol
3-(beta-chlorovinyl)-1-pentyn-3-ol
3-(β-chlorovinyl)-1-pentyn-3-ol
ethyl β-chlorovinyl ethynyl carbinol
Placidyl
β-chlorovinyl ethyl ethynyl carbinol
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Placidyl Cap 200mgcapsule200 mgoralAbbott Laboratories, Limited1956-12-312008-06-10Canada
Placidyl Cap 500mgcapsule500 mgoralAbbott Laboratories, Limited1952-12-312008-06-06Canada
Placidyl Cap 750mgcapsule750 mgoralAbbott Laboratories, Limited1971-12-312008-06-06Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ArvynolPfizer
NostelDainippon
PlacidylAbbott
RoeridormPfizer-Roerig
SerenesilAbbott
Brand mixturesNot Available
SaltsNot Available
Categories
UNII6EIM3851UZ
CAS number113-18-8
WeightAverage: 144.599
Monoisotopic: 144.034192617
Chemical FormulaC7H9ClO
InChI KeyInChIKey=ZEHYJZXQEQOSON-AATRIKPKSA-N
InChI
InChI=1S/C7H9ClO/c1-3-7(9,4-2)5-6-8/h1,5-6,9H,4H2,2H3/b6-5+
IUPAC Name
1-chloro-3-ethylpent-1-en-4-yn-3-ol
SMILES
[H]C(Cl)=CC(O)(CC)C#C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as ynones. These are organic compounds containing the ynone functional group, an alpha,beta unsaturated ketone group with the general structure RC#C-C(=O)R' (R' not H).
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbonyl compounds
Sub ClassAlpha,beta-unsaturated carbonyl compounds
Direct ParentYnones
Alternative Parents
Substituents
  • Ynone
  • Tertiary alcohol
  • Chloroalkene
  • Haloalkene
  • Vinyl halide
  • Vinyl chloride
  • Hydrocarbon derivative
  • Organochloride
  • Organohalogen compound
  • Alcohol
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed for short-term hypnotic therapy in the management of insomnia for periods of up to one week in duration; however, this medication generally has been replaced by other sedative-hypnotic agents.
PharmacodynamicsEthchlorvynol is a sedative drug and schedule IV (USA) controlled substance. It produces cerebral depression, however the exact mechanism of action is not known.
Mechanism of actionAlthough the exact mechanism of action is unknown, ethchlorvynol appears to depress the central nervous system in a manner similar to that of barbiturates. Barbiturates bind at a distinct binding sites associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
Related Articles
AbsorptionRapidly absorbed from gastrointestinal tract.
Volume of distributionNot Available
Protein binding35-50%
Metabolism

About 90% of a dose is metabolized in the liver. Some ethchlorvynol may also be metabolized in the kidneys. Ethchlorvynol and metabolites undergo extensive enterohepatic recirculation.

Route of eliminationNot Available
Half lifePlasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.
ClearanceNot Available
ToxicitySymptoms of overdose include thrombocytopenia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9965
Blood Brain Barrier+0.9685
Caco-2 permeable+0.646
P-glycoprotein substrateNon-substrate0.743
P-glycoprotein inhibitor INon-inhibitor0.9023
P-glycoprotein inhibitor IINon-inhibitor0.9672
Renal organic cation transporterNon-inhibitor0.9589
CYP450 2C9 substrateNon-substrate0.7267
CYP450 2D6 substrateNon-substrate0.9
CYP450 3A4 substrateNon-substrate0.6176
CYP450 1A2 substrateNon-inhibitor0.5224
CYP450 2C9 inhibitorNon-inhibitor0.6241
CYP450 2D6 inhibitorNon-inhibitor0.9316
CYP450 2C19 inhibitorInhibitor0.5539
CYP450 3A4 inhibitorNon-inhibitor0.7814
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7382
Ames testAMES toxic0.867
CarcinogenicityCarcinogens 0.8102
BiodegradationNot ready biodegradable0.9614
Rat acute toxicity2.7881 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9406
hERG inhibition (predictor II)Non-inhibitor0.9289
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Banner pharmacaps inc
  • Abbott laboratories pharmaceutical products div
PackagersNot Available
Dosage forms
FormRouteStrength
Capsuleoral200 mg
Capsuleoral500 mg
Capsuleoral750 mg
PricesNot Available
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
boiling point28.5-30Bayley, A. and McLamore, W.M.; U.S. Patent 2,746,900; May 22,1956; assigned to Chas. Pfizer & Co., Inc.
logP1.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.143 mg/mLALOGPS
logP1.45ALOGPS
logP1.62ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)12.88ChemAxon
pKa (Strongest Basic)-3.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area20.23 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity38.64 m3·mol-1ChemAxon
Polarizability14.77 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Bayley, A. and McLamore, W.M.; U.S. Patent 2,746,900; May 22,1956; assigned to Chas.
Pfizer & Co., Inc.

General ReferencesNot Available
External Links
ATC CodesN05CM08
AHFS Codes
  • 28:24.92
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alprazolam.
AmisulprideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amperozide.
AripiprazoleThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Asenapine.
AzaperoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Azaperone.
AzelastineEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ethchlorvynol.
BaclofenThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Benzyl alcohol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
BrimonidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bupivacaine.
BuprenorphineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butabarbital.
ButacaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butorphanol.
CarbamazepineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chloroprocaine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cinchocaine.
CitalopramThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clorazepate.
ClozapineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clozapine.
CocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Codeine.
CyclizineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cyclobenzaprine.
CyproheptadineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dexmedetomidine.
DextromoramideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Diazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
DoxylamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
DroperidolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Enflurane.
EntacaponeThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Entacapone.
EscitalopramThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Eszopiclone.
EthanolEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Ethchlorvynol.
EthosuximideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etomidate.
EtoperidoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fentanyl.
FexofenadineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fospropofol.
GabapentinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Hydromorphone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
HydroxyzineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Isoflurane.
KetamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lidocaine.
LithiumThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethchlorvynol.
LoxapineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Meprobamate.
MesoridazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methylphenobarbital.
MetyrosineEthchlorvynol may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Midazolam.
MilnacipranThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
MirtazapineEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ethchlorvynol.
MolindoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Morphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.
NabiloneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nalbuphine.
NitrazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Opium.
OrphenadrineEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ethchlorvynol.
OsanetantThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxymorphone.
PaliperidoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Paliperidone.
ParaldehydeEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Ethchlorvynol.
ParoxetineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pentobarbital.
PerampanelThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pethidine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pomalidomide.
PramipexoleEthchlorvynol may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pregabalin.
PrilocaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Procaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Quetiapine.
RamelteonThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Reserpine.
RisperidoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Risperidone.
RomifidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Romifidine.
RopiniroleEthchlorvynol may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ropivacaine.
RotigotineEthchlorvynol may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ethchlorvynol.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Secobarbital.
SertindoleThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sodium oxybate.
StiripentolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sufentanil.
SulpirideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sulpiride.
SuvorexantThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Temazepam.
TetrabenazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetrodotoxin.
ThalidomideEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ethchlorvynol.
ThiamylalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tramadol.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Triflupromazine.
TrimipramineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Valproic Acid.
VigabatrinThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zolpidem.
ZonisamideThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol
  • Take with food to reduce irritation.

Targets

Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. Smeyatsky N, Baldwin D, Botros W, Gura R, Kurian T, Lambert MT, Patel AG, Steinert J, Priest RG: The treatment of sleep disorders. S Afr Med J. 1992 May 2;Suppl:1-8. [PubMed:1585214 ]
  2. ChEMBL Compound Report Card [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23